If strong FOXM1 expression is confirmed in surgical patients that have early stage I/II cancer and no lymph node metastasis or well/moderately differentiated carcinoma, adjuvant therapy and frequent follow-up might be suggested [43]. This evidence concerns the gene FOXM1 and metastatic malignant neoplasm in the lymph nodes.